



Resource impact statement

Resource impact

Published: 28 September 2022

www.nice.org.uk

Cancer Drugs Fund technology

NICE has recommended atezolizumab for use within the Cancer Drugs Fund as adjuvant treatment after complete tumour resection in adults with stage 2 to 3a non-small cell lung cancer (NSCLC) whose tumours have the programmed cell death ligand-1 (PD-L1) biomarker expression on at least 50% or more of tumour cells (TC) and whose disease has not progressed after platinum-based adjuvant chemotherapy. It is recommended only if the company provides atezolizumab according to the managed access agreement.

The recommendation is not intended to affect treatment with atezolizumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Atezolizumab will be available to the NHS in line with the [managed access agreement](#) with NHS England. As part of this, NHS England and Roche have a commercial arrangement (simple discount). This makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence.

It is estimated that around 1,200 people per year with NSCLC are eligible for treatment with atezolizumab.

The resource impact of atezolizumab will be covered by the Cancer Drugs Fund budget. The committee recognised that atezolizumab is a promising treatment option which could reduce the risk of disease recurrence for this group of people in a potentially curative part of the treatment pathway. However, there is not enough clinical and cost-effectiveness evidence to recommend it for routine use in the NHS. Therefore, atezolizumab is recommended for use in the Cancer Drugs Fund.

More evidence on atezolizumab is being collected until the second interim overall survival analysis results of the IMPower010 are available. After this, NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then. Further information can be found in [NHS England's Appraisal and Funding of Cancer Drugs from July 2016 \(including the new Cancer Drugs Fund\) - A new deal for patients, taxpayers and industry](#).

This technology is commissioned by NHS England. Providers are NHS hospital trusts.